undamentalytics Newsletter
Sign in

Ispecimen Inc. income statement

In fiscal 2025, Ispecimen Inc. reported revenue of $1.9m, down 79.2% on the year before, operating income of −$9.0m (a -465.4% margin) and net income of −$10.5m, or −$2.28 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue8111010920
Cost of revenue4555521
Gross profit566540−0
Research and development01121——
Selling and marketing2234524
General and administrative2676633
Operating income−2−6−10−11−13−9−9
Interest expense220000—
Income tax000————
Net income−5−9−10−11−12−10−11
Diluted EPS−$49.70−$20.90−$1.16−$24.55−$17.58−$2.28—
Diluted shares (average)—————5m—
EBITDA−2−6−10−9−10−7−9

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ISPC vs YDESISPC vs QSIACON vs ISPC

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Ispecimen Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ispecimen Inc.